Siddha or Ayurvedha is a treasure of India with an ample of classical literary
evidence, the safety and effectiveness of these medicines are still under debate among both adherents and skeptics. Though many of the remedies have been in use for hundreds of years, critics argue the claims of therapeutic efficacy of traditional medicine. In this aspect through this research study, we have hypothesized a scientific basis for Siddha herbal regimen Kabasura kudineer and Siddha herbomineral regimen Brammanandha Bairavam to have possible clinical efficacy for the prevention and management of COVID-19 Stage-1 infection thereby enabling the disease management and to aid in inhibiting the progression of COVID-19 to stage 2 and stage-3. Coronavirus: Siddha treatment has 100% success rate, claims Tamil Nadu minister “There is a 100% success rate,” the state’s Development Minister K Pandiarajan said. “We are not endangering lives. Siddha is a trump card for us. We are blending Siddha, Yoga and Ayurveda. There is no empirical verification but there is enough history. People have faith. We are documenting many cases now.” Pandiarajan added that “Siddha doesn’t have the last mile – ventilator or oxygen support”, and so “allopathy takes over for such cases”. Such cases are less than 3% of the total, he said. Essentially, he meant that the treatment would work for mild cases and not serious ones. Siddha not proven through documented studies, trials and results’ However, the scientific community was skeptical and urged caution. “We have nothing against it but the only problem is Siddha is not proven through documented studies, trials and results The treatment is known to involve use of heavy metals leading to kidney issues in the long run. But allopathy goes through trials with animals first, then sick patients and healthy people. That’s why Siddha isn’t accepted internationally There is no scientific evidence of alternative cures for the coronavirus. Efforts are being made worldwide to find a vaccine for the disease, with a few inoculation candidates progressing to the human trial stage. THANK YOU